Sunshine Biopharma Inc. (SBFMW) stock
Close on Oct 30, 2026Market cap $11.36MP/E –Yield –
Sunshine Biopharma Inc. saw revenue fall 2.7% to $35.35M over the twelve months to Jun 30, 2026. Free cash flow was -$5.37M. At the latest close the market valued the company at $11.36M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $11.36M
- P/E ratio
- –
- Price to sales
- 0.32
- Price to book
- 0.41
- Dividend yield
- –
- Free cash flow yield
- -47.29%
Fundamentals
- Revenue
- $35.35M
- Net income
- -$5.83M
- EPS, diluted
- -$2.00
- Free cash flow
- -$5.37M
- Book value per share
- $20.17
- Diluted shares
- 1M
Trading
- Previous close
- $0.03
- Open
- $0.03
- Day's range
- $0.03 – $0.03
- Volume
- 5,001
- Average volume (20 days)
- 6,979
- 52-week range
- $0.20 – $464.00
- RSI (14 days)
- 45.5
- Volatility (1 year)
- 7328.2%
- Relative volume
- 0.24×
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | SBFMW | S&P 500 | Difference | SBFMW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -51.3% | -0.9% | −50.4 pts | ||
| 3 months | -40.7% | +2.1% | −42.8 pts | ||
| Year to date | -86.6% | +11.7% | −98.3 pts | ||
| 1 year | -91.2% | +12.4% | −103.6 pts | ||
| 3 years | -91.2% | +88.6% | −179.8 pts | -55.5% | +23.5% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sunshine Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- Results
- News
About Sunshine Biopharma
Pharmaceutical Preparations
Sunshine Biopharma Inc. is a pharmaceutical company engaged in the research, development, and commercialization of medicines across therapeutic areas such as oncology and antivirals. Through its subsidiary Nora Pharma, the company offers generic prescription medications addressing cardiovascular health, central nervous system disorders, oncology, diabetes, and other conditions. It also operates a subsidiary named Sunshine Biopharma Canada, which develops and sells over-the-counter dietary supplements. In addition, Sunshine Biopharma conducts proprietary research programs focused on an mRNA-based therapy for liver cancer and a protease inhibitor targeting SARS Coronaviruses. Its customers include pharmacies and consumers.
Company profile, executives and historySunshine Biopharma stock: common questions
What is Sunshine Biopharma's stock price?
SBFMW closed at $0.03 on Oct 30, 2026, up 2.00% on the day. Over the past 52 weeks it traded between $0.20 and $464.00.
What is Sunshine Biopharma's market cap?
Sunshine Biopharma was worth $11.36M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is SBFMW's P/E ratio?
Sunshine Biopharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$2.00), so it has no meaningful P/E ratio.
How much revenue does Sunshine Biopharma make?
Sunshine Biopharma reported revenue of $35.35M for the twelve months to Jun 30, 2026, down 2.7% from a year earlier.
Does Sunshine Biopharma pay a dividend?
No. Sunshine Biopharma has not paid a cash dividend over the last twelve months.
How has SBFMW stock performed over the past year?
Including dividends, SBFMW returned -91.2% over the past year, against +12.4% for the S&P 500.
Who are Sunshine Biopharma's competitors?
Companies most similar to Sunshine Biopharma by business, industry and size include MCUJF, BHST, JAGX, TNXP, LXRX.